Topics

Promega and Merck collaborate to develop MSI companion diagnostic for use with anti-PD-1 therapy

02:37 EST 8 Nov 2019 | News-Medical.net

Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite instability technology as an on-label, solid tumor companion diagnostic for use with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).

Original Article: Promega and Merck collaborate to develop MSI companion diagnostic for use with anti-PD-1 therapy

NEXT ARTICLE

More From BioPortfolio on "Promega and Merck collaborate to develop MSI companion diagnostic for use with anti-PD-1 therapy"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...